Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 15, 2026, 2:17 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1177–1200 of 1,869 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: First Treatment Period Clear all

Conditions: Endograft Implantation to Repair Abdominal Aortic Aneurysm
Interventions: Contrast Enhanced Ultrasound (Contrast Agent: OptisonTM); Procedure
Lead sponsor: University of Michigan; Other
Eligibility: 18 Years and older
Enrollment: 4 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2011
U.S. locations: 1
States / cities: Ann Arbor, Michigan

Conditions: Multiple Sclerosis, Multiple Sclerosis-Relapsing-Remitting, Multiple Sclerosis, Secondary Progressive
Interventions: Acute Intermittent Hypoxia, Sham-Acute Intermittent Hypoxia; Other
Lead sponsor: Shirley Ryan AbilityLab; Other
Eligibility: 18 Years to 75 Years
Enrollment: 21 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2027
U.S. locations: 1
States / cities: Chicago, Illinois

Conditions: Diabetes, Diabetes Mellitus, Type 2
Interventions: liraglutide, placebo, moxifloxacin, electrocardiogram (ECG); Drug · Procedure
Lead sponsor: Novo Nordisk A/S; Industry
Eligibility: 18 Years to 45 Years
Enrollment: 64 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2006
U.S. locations: 1
States / cities: Fargo, North Dakota

Conditions: Myelodysplastic Syndromes
Interventions: Dasatinib; Drug
Lead sponsor: H. Lee Moffitt Cancer Center and Research Institute; Other
Eligibility: 18 Years and older
Enrollment: 18 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2012
U.S. locations: 1
States / cities: Tampa, Florida

Conditions: Fibromyalgia
Interventions: Placebo, Neurotropin; Drug
Lead sponsor: National Institute of Nursing Research (NINR); NIH
Eligibility: 18 Years and older · Female only
Enrollment: 56 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2015
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Alcoholism, Alcohol Use Disorder (AUD)
Interventions: Topiramate, Medical Management, Inactive Placebo; Drug · Behavioral
Lead sponsor: University of Pennsylvania; Other
Eligibility: 18 Years to 70 Years
Enrollment: 320 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2020
U.S. locations: 2
States / cities: Philadelphia, Pennsylvania

Conditions: Invasive Aspergillosis
Interventions: Olorofim, AmBisome®; Drug
Lead sponsor: F2G Ltd; Industry
Eligibility: 18 Years and older
Enrollment: 225 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2026
U.S. locations: 24
States / cities: Birmingham, Alabama • Duarte, California • Sacramento, California + 21 more

Conditions: Schizophrenia, Impulsive Behavior
Interventions: Nicotine Patch, 7 Mg/24 Hr, Placebo patch; Drug
Lead sponsor: Vanderbilt University Medical Center; Other
Eligibility: 18 Years to 65 Years
Enrollment: 18 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2019 – 2020
U.S. locations: 1
States / cities: Nashville, Tennessee

Conditions: Moderate to Severe Plaque Psoriasis
Interventions: bimekizumab, ustekinumab, placebo; Drug
Lead sponsor: UCB Biopharma SRL; Industry
Eligibility: 6 Years to 17 Years
Enrollment: 176 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2030
U.S. locations: 7
States / cities: Fountain Valley, California • Los Angeles, California • Northridge, California + 4 more

Conditions: Myelodysplastic Syndromes, Chronic Myelomonocytic Leukemia, Acute Myeloid Leukemia
Interventions: ASTX727, Dacogen; Drug
Lead sponsor: Astex Pharmaceuticals, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 227 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2023
U.S. locations: 39
States / cities: Anniston, Alabama • Phoenix, Arizona • Tucson, Arizona + 32 more

Conditions: Childhood Absence Epilepsy, Petit Mal Epilepsy, Epilepsy, Seizures
Interventions: Ethosuximide, Lamotrigine, Valproic acid; Drug
Lead sponsor: Children's Hospital Medical Center, Cincinnati; Other
Eligibility: 30 Months to 13 Years
Enrollment: 453 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2004 – 2016
U.S. locations: 31
States / cities: Birmingham, Alabama • Phoenix, Arizona • Little Rock, Arkansas + 28 more

Conditions: Non-Hodgkin Lymphoma, Non-Hodgkin's Lymphoma, Relapsed, Non-Hodgkin's Lymphoma Refractory
Interventions: Bridging radiotherapy (BRT), Conditioning chemotherapy, CAR T-cell product; Radiation · Drug · Biological
Lead sponsor: Memorial Sloan Kettering Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2027
U.S. locations: 7
States / cities: Basking Ridge, New Jersey • Middletown, New Jersey • Montvale, New Jersey + 4 more

Conditions: Paroxysmal Nocturnal Hemoglobinuria (PNH)
Interventions: Danicopan, Eculizumab; Drug
Lead sponsor: Alexion Pharmaceuticals, Inc.; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 12 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2023
U.S. locations: 2
States / cities: Baltimore, Maryland • Cleveland, Ohio

Conditions: Cancer
Interventions: Legal Navigation; Behavioral
Lead sponsor: University of Alabama at Birmingham; Other
Eligibility: 18 Years and older
Enrollment: 50 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2027
U.S. locations: 1
States / cities: Birmingham, Alabama

Conditions: Advanced Solid Tumor
Interventions: STX-001, Keytruda®; Biological
Lead sponsor: Strand Therapeutics Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 108 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2028
U.S. locations: 6
States / cities: Scottsdale, Arizona • Beverly Hills, California • Cleveland, Ohio + 3 more

Conditions: Fistula Stenosis
Interventions: Paclitaxel, Standard Therapy; Drug · Procedure
Lead sponsor: Englewood Hospital and Medical Center; Other
Eligibility: 18 Years and older
Enrollment: 10 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2015
U.S. locations: 1
States / cities: Englewood, New Jersey

Conditions: Suicidal Thoughts and Behaviors
Interventions: PRECISE; Behavioral
Lead sponsor: University of California, San Diego; Other
Eligibility: 18 Years to 65 Years
Enrollment: 70 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2030
U.S. locations: 1
States / cities: San Diego, California

Conditions: Attention Deficit Hyperactivity Disorder, Nicotine Dependence
Interventions: Transdermal Nicotine Patch, Lis-dexamphetamine (Vyvanse), Placebo; Drug
Lead sponsor: Duke University; Other
Eligibility: 18 Years to 50 Years
Enrollment: 32 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2007 – 2011
U.S. locations: 1
States / cities: Durham, North Carolina

Conditions: Moderate to Severe Plaque-type Psoriasis
Interventions: secukinumab 150 mg, secukinumab 300 mg, placebo; Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 18 Years and older
Enrollment: 177 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2016
U.S. locations: 18
States / cities: Birmingham, Alabama • Mobile, Alabama • Glendale, Arizona + 15 more

Conditions: Chronic Stroke
Interventions: LSVT®BIG Intervention, Waitlist Control; Behavioral
Lead sponsor: University of Missouri-Columbia; Other
Eligibility: 18 Years and older
Enrollment: 5 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2019
U.S. locations: 1
States / cities: Columbia, Missouri

Conditions: Down Syndrome, Trisomy 21
Interventions: EXPO, EXPO Extended, EXPO Foundations; Behavioral
Lead sponsor: Colorado State University; Other
Eligibility: 36 Months to 72 Months
Enrollment: 150 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2030
U.S. locations: 1
States / cities: Fort Collins, Colorado

Conditions: Fibrous Dysplasia/McCune-Albright Syndrome
Interventions: MRI-based Neuroimaging, Non-contrast MRI, 18F-FDG-PET/CT, 18F-NaF-PET/CT; Diagnostic Test
Lead sponsor: Boston Children's Hospital; Other
Eligibility: 10 Years to 45 Years
Enrollment: 37 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021 – 2025
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Osteoarthritis of the Knee
Interventions: 1.2% Sodium Hyaluronate, Buffered Saline; Device
Lead sponsor: Ferring Pharmaceuticals; Industry
Eligibility: 40 Years and older
Enrollment: 596 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2011
U.S. locations: 34
States / cities: Homewood, Alabama • Tucson, Arizona • Hot Springs, Arkansas + 30 more

Conditions: Non-Hodgkin's Lymphoma, Diffuse Large B-Cell Lymphoma, DLBCL, NHL
Interventions: DA-EPOCH, Rituximab, CHOP, Acalabrutinib; Drug · Biological
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years and older
Enrollment: 132 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2031
U.S. locations: 1
States / cities: Bethesda, Maryland

Search by objective public record fields.

Contrast Enhanced Ultrasound vs. Computed Tomographic Angiography in the Detection of Endoleaks Following AAA Repair

Intermittent Hypoxia in Persons With Multiple Sclerosis

Effect of Liraglutide on Heart Frequency in Healthy Volunteers

Study of Oral Dasatinib in Subjects With Myelodysplastic Syndrome (MDS) and Excess Marrow Blasts

Neurotropin Treatment of Fibromyalgia

A Randomized, Double-blind Placebo-Controlled Pharmacogenetic Study of Topiramate in European-American Heavy Drinkers

Olorofim Aspergillus Infection Study

Effects of Transdermal Nicotine on Response Inhibition to Emotional Cues in Schizophrenia

A Study to Evaluate the Efficacy and Safety of Bimekizumab Compared to Ustekinumab in Children and Adolescents From 6 Years to Less Than 18 Years of Age With Moderate to Severe Plaque Psoriasis

Study of ASTX727 vs IV Decitabine in Participants With MDS, CMML, and AML

Childhood Absence Epilepsy Rx PK-PD-Pharmacogenetics Study

A Study of Radiation Therapy Before CAR T Cell Therapy for People With B Cell Lymphoma

Study of Danicopan in Participants With Paroxysmal Nocturnal Hemoglobinuria With Inadequate Response to Eculizumab

Legal Evaluation for Greater Access to Cancer Care (LEGAL-CARE)

Phase 1/2 Study of Intratumoral Injection of STX-001 in Advanced Solid Tumors as Monotherapy or in Combination With Pembrolizumab

Paclitaxel for the Treatment of Upper-Extremity Arteriovenous Access Fistula Stenosis

Development of PRECISE: A Data Driven Personalized Suicide Prevention Intervention

Attention Deficit Hyperactivity Disorder (ADHD) Smoking Cessation Study

First Study of Secukinumab in Pre-filled Syringes in Subjects With Chronic Plaque-type Psoriasis: Response at 12 Weeks

Feasibility of the Lee Silverman Voice Treatment®-BIG Intervention in Stroke

Executive Function Play Opportunities for Children With Down Syndrome

Pain in Fibrous Dysplasia

Investigation of 1.2% Sodium Hyaluronate for Treatment of Painful Chronic Osteoarthritis of the Knee

Acalabrutinib With DA-EPOCH-R or R-CHOP for People With Untreated Diffuse Large B-cell Lymphoma